Influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza annual report, 2015
DOI:
https://doi.org/10.33321/cdi.2017.41.20Keywords:
influenza, annual reportAbstract
As part of its role in the World Health Organization’s (WHO) Global Influenza Surveillance and Response System, the WHO Collaborating Centre for Reference and Research on Influenza in Melbourne received a total of 5,557 influenza positive samples during 2015. Viruses were analysed for their antigenic, genetic and antiviral susceptibility properties. In 2015, influenza B viruses predominated over influenza A(H1)pdm09 and A(H3) viruses, accounting for a total of 58% of all viruses analysed. The vast majority of A(H1)pdm09, A(H3) and influenza B viruses analysed at the Centre were found to be antigenically similar to the respective WHO recommended vaccine strains for the Southern Hemisphere in 2015. However, phylogenetic analysis of a selection of viruses indicated that the majority of circulating A(H3) viruses were genetically distinct from the WHO recommended strain for 2015, resulting in an update to the recommended vaccine strain for the Southern Hemisphere for 2016. With an increasing predominance of B/Victoria lineage viruses over B/Yamagata lineage viruses through the course of 2015, WHO also updated the recommended influenza B strain in the trivalent influenza vaccine for 2016. Of more than 3,300 samples tested for resistance to the neuraminidase inhibitors oseltamivir and zanamivir, only 1 A(H1)pdm09 virus showed highly reduced inhibition by oseltamivir. The Centre undertook primary isolation of candidate vaccine viruses directly into eggs, and in 2015 a total of 45 viruses were successfully isolated in eggs. Commun Dis Intell 2017;41(2):E150–E160.
Downloads
References
Oh DY, Barr IG, Mosse JA, Laurie KL. MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J Clin Microbiol 2008;46(7):2189–2194.
Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972;70(4):767–777.
Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N, et al. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? J Virol 2010;84(13):6769–6781.
Hurt AC, Okomo-Adhiambo M, Gubareva LV. The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors. Methods Mol Biol 2012;865:115–125.
Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo-de-Andrade H, Besselaar T, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014. Antiviral Res 2015;117:27–38.
WHO Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva: World Health Organization; 2011.
Sullivan SG, Chow MK, Barr IG, Kelso A. Influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza annual report, 2014. Commun Dis Intell 2015;39(4):E602–E611.
Australian Government Department of Health. National Notifiable Diseases Surveillance System. 2015. Available from: http://www9.health.gov.au/cda/source/cda-index.cfm Accessed on 17 August 2016.
Fielding JE, Regan AK, Dalton CB, Chilver MB, Sullivan SG. How severe was the 2015 influenza season in Australia? Med J Aust 2016;204(2):60–61.
Institute of Environmental Science and Research Ltd. Influenza Weekly Update 2015/39; 2015.
Australian Government Department of Health. Australian Influenza Surveillance Report No 10: 26 September to 9 October 2015.
Kaczmarek M, Owen R, Barr IG. Annual report of the National Influenza Surveillance Scheme, 2008. Commun Dis Intell 2010;34(1):8–22.
Barr IG, Vijaykrishna D, Sullivan SG. Differential age susceptibility to influenza B/Victoria lineage viruses in the 2015 Australian influenza season. Euro Surveill 2016;21(4) doi: 10.2807/1560-7917.
Fielding JE, Levy A, Chilver MB, Deng YM, Regan AK, Grant KA, et al. Effectiveness of seasonal influenza vaccine in Australia, 2015: An epidemiological, antigenic and phylogenetic assessment. Vaccine 2016;34(41):4905–4912.
Barr IG, Russell C, Besselaar TG, Cox NJ, Daniels RS, Donis R, et al. WHO recommendations for the viruses used in the 2013–2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013. Vaccine 2014;32(37):4713–4725.
Chambers C, Skowronski DM, Sabaiduc S, Winter AL, Dickinson JA, De Serres G, et al. Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016. Euro Surveill 2016;21(11):30168.
Emborg HD, Krause TG, Nielsen L, Thomsen MK, Christiansen CB, Skov MN, et al. Influenza vaccine effectiveness in adults 65 years and older, Denmark, 2015/16 – a rapid epidemiological and virological assessment. Euro Surveill 2016;21(14) doi: 10.2807/1560-7917
Downloads
Published
How to Cite
License
Copyright (c) 2017 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
